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3.4% in an observation unit to adults. Only 4.1% of the observations satisfied the
French paediatric short-stay definition (patient in a bed monitored hourly). Com-
pared to the clinicians’ prognosticated rate, 1.3% less children were admitted as
in-patients. CONCLUSIONS: Despite the absence of financial and regulatory frame
in Belgium, observation is a frequent modality of care. Observation helped to refine
diagnosis and treatments and to reduce in-patient admission rate. However, with
regards to the French guidelines less than 5% could be qualified as paediatric A&E
short-stay. Flexible observation units should be recommended.KEYWORDS: Emer-
gency, paediatrics, short-stay, observation status
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OBJECTIVES: Explore the variability of two sets of tariffs/public prices across Au-
tonomous Communities (ACs) in Spain. METHODS: Tariffs/public prices for DRGs
and ICD-9 procedure items from all 17 Spanish AC were extracted from official
listings. For ICD-9, items appearing in at least 5 ACs were selected. Per item, vari-
ability in tariffs/public prices across ACs was measured using the coefficient of
variation (CV) where greater CV indicates larger variability. Variability in DRG lev-
els across ACs was assessed for a sub-set of 16 items. We developed a simple
relative index whereby a tariff in a region was divided by the average tariff across
all regions and then an overall index was computed as the simple mean of all items
for each AC. RESULTS:Nine out of 17 ACs list DRGs. Navarra had the most complete
list (681 items) and Catalonia the least complete (50 items). The lowest CV was for
“spinal procedures” (DRG #4, mean: 10,335€, CV: 0.016, N2) and the greatest for
“abdominal interventions to neonates” (DRG 624, mean: 8139€, CV: 1248, N6). On
average, across the sub-set of 16 DRGs, Catalonian tariffs were 63% below and La
Rioja tariffs were 31% above the average across 9 ACs. ICD-9 tariffs were identified
in 6 out of 17 ACs, and variability for 48 codes that were listed in at least 4 ACs was
lowest for “repair of uterine support structures” (ICD-9 #69.2, mean: 1210€, CV: 0.07,
N4) and greatest for “local excision of breast lesion” (ICD-9 #85.21, mean: 710€, CV:
0.83, N4).CONCLUSIONS:Results show great variability amongst AC tariff listings
in Spain. Some ACs tend towards consistently higher or lower tariff levels, com-
pared to the average across ACs. Differences are difficult to explain and suggest
that tariffs and pubic prices do not reflect actual costs, but may be arbitrary esti-
mates.
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OBJECTIVES: As evidence and experience of telemonitoring grows, health care
payers are confronted with multiple challenges to reimburse these new healthcare
solutions. This study evaluated the current reimbursement systems in five Euro-
pean markets (France, Germany, Italy, Spain, and the UK) to determine readiness
for telemonitoring and to identify changes required to permit telemonitoring to
develop in the future. METHODS: To identify current telemonitoring funding, we
reviewed the sources and mechanisms used to pay for pilot projects, and then
reviewed national and regional health care funding systems to evaluate the read-
iness to finance telemonitoring. RESULTS: There are important differences in fi-
nancing telemonitoring among European countries. While pilots exist in all coun-
tries, these are financed on a project basis from European Union, national or
regional funds, outside regular healthcare budgets. Budget silos, disease reference
group (DRG) changes and contractual funding are key barriers to payer readiness
for telemonitoring. In Germany, only one telemonitoring DRG act is defined, while
in France and Italy, defining telemonitoring acts for reimbursement is underway.
In these countries, payers are reluctant to pay for the monitoring and alert service
component. In Spain, regional authorities are advancing pilots at different speeds
but system reforms have not yet been undertaken. Only in the UK, the English NHS
has moved from pilots to deployment through financing at the Primary Care Trust
level. CONCLUSIONS: European reimbursement systems do not yet accommodate
telemonitoring, and pilots and device purchases will not sustain this therapeutic
solution. To enable telemonitoring, payers need to establish new codes and rules to
pay for telemonitoring acts by health care professionals, and decide how to pay for
the most complex element: the monitoring and alert service component. Options
include: no reimbursement (the current option), a periodic fixed fee or capitation.
Any option requires careful framing and the benefits of telemonitoring need fur-
ther evaluation.
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OBJECTIVES: To assess the impact of different formats of G-BA‘s (Federal Joint
Committee) directives had on the prescription behavior of health care profession-
als (HCPs) prior to the introduction of the AMNOG legislation (i.e. Directives re-
structuring the German pharmaceutical market).METHODS:A retrospective study
of the IQWiG’s (Institute for Quality and Efficiency in Healthcare) review of phar-
maceutical products covered by a G-BA directive during a 5-year period (2005-2010).
An event list reporting the interaction of G-BA, IQWiG and BMG (German Minister
of Health) was compiled by systematic searches of official websites. Regression
analyses retrieved from IMS data bases (Intercontinental Marketing Services) were
conducted defining a 95% confidence interval. Time points where actual sales ex-
ceeded or deceeded this confidence interval were reconciled with the list of events
concluding if and what kind of events had impacted unit sales. RESULTS: G-BA
required a mean of 1304 days to generate a directive followed by 567 days required
by IQWiG to complete its review. IQWiG achieved a mean output of 15 projects per
year, which is half of what NICE achieved in the same period. The format of the
final directive had a strong influence on the overall review. These findings indicate
that G-BA’s directives did not influence the annual number of prescriptions during
the five year period. CONCLUSIONS: The new set of laws – commonly known as
AMNOG is targeting two important weaknesses of the previous systems, which are
clearly identified by this study. Thus, clear ambitious timelines should be defined,
especially for the most time consuming review stages, namely completion of the
report plan and adherence to the principle of evidence based medicine for all
reviews.
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OBJECTIVES: To review the barriers and opportunities in market access for
biosimilars. METHODS: Both primary & secondary research were used in this
study. Primary research was conducted with payers, physicians, pharmaceuticals
and biosimilar manufactures. RESULTS: The US and EU are currently the largest
consumers of biologics in the world; however, other markets are expected to see
strong growth in their use of biologics over the next few years. Although many
biologics are expected to go off-patent in the next few years, (thereby creating an
attractive opportunity for biosimilars); the complex structure of biologics makes
the manufacturing process of biosimilars extremely difficult, and with EU legisla-
tion currently requiring phase I-III clinical trials to be conducted for all new bio-
similars the developmental costs and barriers to entry of biosimilars are high. With
respect to the costs per treatment, the price of biologics are significantly higher
than for small molecules creating a use-limiting factor in many markets; for this
reason biosimilars are recognised by payers and physicians as being cost-effective
in the sense of being able to provide the same treatment but at a lower cost (20%
cheaper). However, payers confirmed that cost-saving alone will not ensure access
for biosimilars and physicians are hesitant to adopt biosimilars due to safety and
efficacy concerns. CONCLUSIONS: With the use of biologics rapidly increasing,
patent expiries expected to occur in the near future and the low numbers of com-
petitors, companies are presented with a new and attractive market with the pro-
duction of biosimilars. Although there are several challenges to entering the mar-
ket (including the intense approval process) biosimilars are recognized and are
treated differently from generics by payers. With drug costs increasing and con-
cerns over the safety and efficacy of biosimilars, reduced costs of biosimilars to-
gether with clinical reassurance will enable broader acceptance and usage of bio-
similars in most markets.
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OBJECTIVES: While the European biosimilars market is still in its infancy, these
products are facing tough market access conditions and have yet to match the
success of small-molecule generics. With the increasing cost consciousness of the
payers and potentially safety concerns, it is imperative to explore the key pricing
and reimbursement drivers and barriers for biosimilars from the payer-lens. In
addition, the research aims to provide insights into strategies for their successful
‘market access’ in the German healthcare system. METHODS: This research was
based on a combination of secondary and primary research to evaluate the key
success factors for biosimilars. Secondary research of published data such as G-
BA’s assessment of biosimilars, current policies, sector-specific research articles
contributed towards a framework to understand the key factors affecting payer’s
attitudes towards biosimilars, which was then validated through a telephone sur-
vey of 10 sickness funds in 2011. RESULTS: A multitude of factors determine price
sustainability for biosimilars in Germany. The attitudes of sickness funds toward
biosimilars vary, which affect price dynamics as well as the cost containment
measures to encourage/ inhibits its use. While the use and prescribing of biosimi-
lars are subject to quotas and guidelines encouraging its use, some sickness funds’
focus on price is moderated by concerns about the safety of biosimilars. Overall, in
order to provide access to these products, payers are increasingly raising data
requirements. CONCLUSIONS: There exits significant inter-payer variability in the
extent of inter-changeability and data expectation from future biosimilars. Payer
expectations vary, based on the stage of the disease/ indications, the level of unmet
need, and the number of available alternatives. In a climate of increasing pricing
concerns, securing marketing approval is no longer the end of the road for biosimi-
lars. Hence, unlike generics, biosimilars cannot be merely ‘sold’ but need to be
‘marketed’.
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